發(fā)布時間：2018-05-26 14:18

  本文選題：DC + CIK��； 參考：《新疆醫(yī)科大學(xué)》2015年碩士論文

【摘要】：目的：通過比較晚期惡性腫瘤患者在DC、CIK、CD3AK細(xì)胞回輸治療前后外周血CD3+T細(xì)胞、CD4+T細(xì)胞、CD8+T細(xì)胞和CD4+T/CD8+T細(xì)胞比值的變化,探討DC、CIK、CD3AK協(xié)同治療對晚期腫瘤患者免疫功能的影響。方法：收集2014年04月—12月我科行DC、CIK、CD3AK協(xié)同治療的晚期惡性腫瘤患者111例,流式細(xì)胞儀檢測治療前后CD3+T細(xì)胞、CD4+T細(xì)胞、CD8+T細(xì)胞的百分比,并計算CD4+ T/CD8+ T細(xì)胞比值。結(jié)果：①晚期惡性腫瘤患者在回輸治療后CD3+T細(xì)胞、CD4+T細(xì)胞百分比及CD4+ T/CD8+ T細(xì)胞的比值有明顯提高,CD8+T細(xì)胞百分比降低(P0.05)；②各病種患者回輸治療后CD3+T細(xì)胞、CD4+T細(xì)胞百分比及CD4+T/CD8+T細(xì)胞的比值提高,CD8+T細(xì)胞百分比降低(P0.05)；③多療程組與單療程組回輸治療后CD3+T細(xì)胞、CD4+T細(xì)胞百分比及CD4+ T/CD8+ T細(xì)胞的比值提高,CD8+T細(xì)胞百分比降低,但多療程組T細(xì)胞亞群變化大于單療程組；④聯(lián)合放化療組與未聯(lián)合組回輸治療后CD3+T細(xì)胞、CD4+T細(xì)胞百分比及CD4+ T/CD8+ T細(xì)胞的比值提高,CD8+T細(xì)胞百分比降低細(xì)胞百分比降低,但聯(lián)合治療組變化大于未聯(lián)合組。結(jié)論：DC、CIK、CD3AK協(xié)同治療能提高晚期腫瘤患者免疫功能；多療程以及聯(lián)合放化療效果更好。
[Abstract]:Objective: to compare the changes of the ratio of CD 4 T cells to CD 8 T cells and CD4 T/CD8 T cells in peripheral CD3 T cells in patients with advanced malignant tumor before and after the patients were treated with DCCIK + CD3AK cells, and to explore the effect of DCCCIK + CD3AK synergistic therapy on the immune function of patients with advanced tumor. Methods: from April to December 2014, 111 patients with advanced malignant tumor treated with DCCCIK CD3AK were collected. The percentage of CD3 T cells, CD4 T cells and CD8 T cells before and after treatment were detected by flow cytometry, and the ratio of CD4 T/CD8 T cells was calculated. Results the percentage of CD3 T cell CD4 T cell and the ratio of CD4 T/CD8 T cell to CD4 T/CD8 T cell were significantly increased in the patients with advanced malignant tumor after retransfusions. The percentage of CD3 T cells in the patients with advanced malignant tumor was significantly decreased after retransfusions. The percentage of CD3 T cells and the ratio of CD4 T/CD8 T cells increased. The percentage of CD3 T cells and the ratio of CD4 T/CD8 T cells increased. However, the changes of T cell subsets in multi-course group were more than those in single-course group. The percentage of CD3 T cell CD4 T cell and the ratio of CD4 T/CD8 T cell to CD4 T/CD8 T cell were decreased after the treatment of combined radiotherapy and chemotherapy, and the ratio of CD4 T/CD8 T cell to CD4 T/CD8 T cell increased. However, the changes in the combined treatment group were greater than those in the uncombined group. Conclusion the immune function of patients with advanced tumor can be improved by the synergistic treatment of CD3AK with the combination of multiple courses of treatment and radiotherapy and chemotherapy.
【學(xué)位授予單位】：新疆醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2015
【分類號】：R730.5

【參考文獻(xiàn)】

相關(guān)期刊論文 前3條

1 王其京;王慧;潘科;;自體CIK、DC-CIK與半合子DC-CIK抗腫瘤免疫反應(yīng)的比較研究(英文)[J];癌癥;2010年07期

2 烏蘭圖雅;王士勇;杜微麗;張暉;張遠(yuǎn);曾雪;劉颯;劉艷萍;張璐;張哲;何英;王佳玲;武秀艷;;晚期肺癌患者免疫功能的系統(tǒng)評價及臨床意義[J];中國肺癌雜志;2010年04期

3 王俞;崔書中;;惡性腫瘤患者的免疫功能狀態(tài)及免疫治療研究進(jìn)展[J];中國腫瘤臨床;2014年13期

，

本文編號：1937538